AN2 Therapeutics Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.
The company mentioned on its website that they use animals for product testing.
“Epetraborole has the potential to meet many of the characteristics of an ideal target product profile. It has demonstrated high levels of efficacy in animal models of NTM infection, it works via a novel mechanism of action, and is well tolerated with a once-daily oral treatment for patients with NTM lung disease. There is only one approved therapy in the United States for patients with pulmonary NTM, and patients and physicians need better options,” said Eric Easom, President and Chief Executive Officer of AN2 Therapeutics. Read the following article
AN2 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. AN2 Therapeutics serves customers worldwide.
Company Website: an2therapeutics.com